PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Positive gross profit growth while CRVO is negative. John Neff would see a clear operational edge over the competitor.
-1.47%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-1.47%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-1.89%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
2.63%
Positive EPS growth while CRVO is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
2.63%
Positive diluted EPS growth while CRVO is negative. John Neff might view this as a strong relative advantage in controlling dilution.
3.22%
Share change of 3.22% while CRVO is at zero. Bruce Berkowitz would see if slight buybacks (or dilution) matter in the bigger picture.
3.22%
Diluted share change of 3.22% while CRVO is zero. Bruce Berkowitz might see a minor difference that could widen over time.
No Data
No Data available this quarter, please select a different quarter.
-50.21%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-50.21%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative 3Y CAGR while CRVO stands at 0.00%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
91.36%
10Y OCF/share CAGR in line with CRVO's 99.92%. Walter Schloss would see both as similarly efficient over the decade.
62.52%
5Y OCF/share CAGR at 50-75% of CRVO's 97.30%. Martin Whitman would question if the firm lags in monetizing revenue effectively.
-48.56%
Negative 3Y OCF/share CAGR while CRVO stands at 57.49%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
94.18%
Similar net income/share CAGR to CRVO's 99.97%. Walter Schloss would see parallel tailwinds or expansions for both firms.
69.28%
5Y net income/share CAGR at 50-75% of CRVO's 98.78%. Martin Whitman might see a shortfall in operational efficiency or brand power.
-24.85%
Negative 3Y CAGR while CRVO is 93.92%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
-50.75%
Both are negative. Martin Whitman suspects the segment is in decline or saddled with persistent unprofitability or write-downs.
-32.62%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
-67.01%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-8.62%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-15.55%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-7.46%
We’re deleveraging while CRVO stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
10.75%
R&D dropping or stable vs. CRVO's 35.86%. David Dodd sees near-term margin benefits if the product pipeline is already strong.
-21.32%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.